期刊
GENES
卷 11, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/genes11070722
关键词
trypanosomatids; neglected tropical diseases; Leishmania; Trypanosoma cruzi; Trypanosoma brucei; drug discovery; in vitro models; in vivo models; genomics; drug resistance
资金
- Natural Sciences and Engineering Research Council of Canada [RGPIN-2017-04480]
- Canada foundation for Innovation [37324]
- Fonds de Recherche du Quebec-Nature et Technologies (FRQNT) scholarship program
Leishmaniasis (Leishmaniaspecies), sleeping sickness (Trypanosoma brucei), and Chagas disease (Trypanosoma cruzi) are devastating and globally spread diseases caused by trypanosomatid parasites. At present, drugs for treating trypanosomatid diseases are far from ideal due to host toxicity, elevated cost, limited access, and increasing rates of drug resistance. Technological advances in parasitology, chemistry, and genomics have unlocked new possibilities for novel drug concepts and compound screening technologies that were previously inaccessible. In this perspective, we discuss current models used in drug-discovery cascades targeting trypanosomatids (from in vitro to in vivo approaches), their use and limitations in a biological context, as well as different examples of recently discovered lead compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据